PharmaMar and Jazz sign $1bn US deal for lung cancer drug lu...

Spain's PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin in the US, which is being teed up for a launch in 2020.

BMS files first drug from triple bet with Celgene shareholde...

Bristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” with former investors in Celgene that could pay out billions if they all successfully make i

FDA backs Astellas/Seattle Genetics bladder cancer drug

The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the stars of this year’s ASCO conference that was considered an almost dead

AZ’s Lynparza inches towards ‘game changer’ okay in pancreat...

Epizyme's sarcoma drug tazemetostat faces key vote from FDA ...

Epizyme’s sarcoma drug tazemetostat is set to go before an influential FDA advisory committee today, following a mixed review from the agency’s own staffers.

BeiGene's Brukinsa fails to beat AbbVie/J&J's Ibrutinib in W...

BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).